Meghan Markle brings magical vibes as her, Prince Harry’s Netflix deal renews
Meghan Markle is getting ready to spice up your Netflix feed with the upcoming season of her lifestyle show, With Love, Meghan.
On Thursday, August 21, the Duchess of Sussex shared a mouth-watering sneak peek into season 2, accompanied by a familiar phrase that’ll transport you back to the ’90s.
“Dare I say, ‘It’s all that….and a bag of chips,’” she captioned a video clip of sizzling potato slices.
The phrase “it’s all that and a bag of chips” originated in the ’90s, popularised by Fab 5 Freddy, the former host of Yo! MTV Raps. Will Smith later used it in his TV show The Fresh Prince of Bel-Air, cementing its place in pop culture history.
The trailer for season 2, released on August 12, gives us a glimpse into the exciting lineup of celebrity guests.
Expect appearances from Mindy Kaling, Roy Choi, Alice Waters, Chrissy Teigen, Tan France, José Andrés, and David Chang, among others.
The season promises to be filled with cooking, crafting, and laughter, showcasing Meghan’s passion for creativity and connection.
The trailer drop comes hot on the heels of Meghan and Prince Harry’s announcement that they’ve extended their partnership with Netflix for future film and television projects.
“We’re proud to extend our partnership with Netflix and expand our work together to include the As ever brand,” Meghan said in a statement.
“My husband and I feel inspired by our partners who work closely with us and our Archewell Productions team to create thoughtful content across genres that resonates globally and celebrates our shared vision.”
Mark your calendars for August 26, when season 2 of With Love, Meghan will premiere on Netflix.
In the meantime, Meghan has been teasing the upcoming season with behind-the-scenes glimpses on her Instagram account. “Cooking up more than pasta (with homemade preserved lemons)…..so much goodness is coming soon,” she captioned a recent video.
The monoclonal antibody INCA44989 is the first-ever treatment for essential thrombocythemia (ET) that may alter the underlying mechanism of disease for patients with mutations of calreticulin (mutCALR), according to a recent phase 1 study. The majority of patients achieved a swift and durable response.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The research outcomes were presented at a late-breaking session during the 2025 European Hematology Association Congress. Notably, the medication also has a very low toxicity profile.
“The overall response rate of roughly 70% is pretty remarkable,” notes Aaron Gerds, MD, study co-author and a hematologist with Cleveland Clinic Cancer Institute. “It’s also very advantageous to have a therapy with a side effect profile like this, as it’s likely to also work well in combination with other medications.”
Background
ET is a myeloproliferative neoplasm with increased risk of thrombosis, hemorrhage and progression to myelofibrosis (MF) or acute myeloid leukemia. Patients with ET often suffer from extreme fatigue, night sweats, fevers, itchy skin, unintentional weight loss and/or enlarged spleen. “Controlling patients’ blood counts is very important to reduce the risk of bleeding or clotting,” explains Dr. Gerds. “However, we not only need therapies that control blood counts and improve symptoms but modify the course of disease and reduce the risk of progression to post-ET myelofibrosis or acute leukemia.”
In recent years, researchers discovered that ET was caused by threedistinct driver mutations: JAK II, MPL and mutCALR. Roughly a quarter of patients with ET have mutCALR, which is associated with lower rates of response to treatment as well as higher risk of transformation to MF. Current treatments control blood counts and mitigate vascular complications for a certain percentage of patients, but don’t address the underlying disease and are not targeted at driver mutations.
“All the existing treatments are non-specific in that they can’t target specific mutations, and most have considerable toxicities,” explained Dr. Gerds. “Hydroxyurea and interferons can achieve disease control in between 30-60% of patients, but they’re accompanied by hair thinning, mouth sores, and in the case of interferons, liver enzyme elevation. They’re also not appropriate for patients with auto immune disorders, as they can lead to depression and other mental health issues.”
Study concept
The mutCALR protein is unique in that it’s actually external to the cell so it’s susceptible to targeting. (JAK II and MPL don’t act in that manner.) Researchers sought to target mutCALR with a monoclonal antibody, which would be expected to have a minimal side effect profile.
Several years ago, researchers conducted preclinical work in that space, deploying INCA33989 to go after mutCALR mutations. They found the therapy had a fairly remarkable response in terms of selectively targeting the mutation.
Study design
Building on the preclinical work, researchers at Cleveland Clinic Cancer Institute participated in a multisite, first-in-human study evaluating INCA33989 for patients with the CALR exon-9 mutation with high-risk ET or MF. Patients received INCA33989 as a monotherapy via IV every two weeks.
Primary endpoints were dose-limiting toxicities or treatment-emergent adverse events. Secondary endpoints included symptom improvement (based on MPN-SAF TSS), treatment response using European LeukemiaNet response criteria and changes in allele burden of mutCALR.
In the ET cohort, there were 49 patients enrolled, with a median age of 60. Initially, patients received a very low dose (24 mg) and over time titrated up to 1,500 mg.
Study outcomes
Sixty-six percent of patients achieved a complete response in terms of normalization of platelet count. “Even for those starting at an incredibly low dose, we were seeing transient responses,” says Dr. Gerds. Eight-nine percent of evaluable patients also had a reduction in mutCALR VAR from their baseline, with 47% achieving a reduction of 20% or more and 21% achieving a reduction of 50% or more.
Perhaps even more importantly, the therapy seems to reduce disease burden. In the trial, a significant number of patients also achieved reductions in allele rates (a rough approximation of disease burden in ET) at a median follow-up of seven weeks. “By comparison, we don’t typically see allele burden reductions with interferons for one to two years,” says Dr. Gerds.
Higher doses of INCA33989 correlated with improved responses. Fortunately, increasing the dose did not seem to cause many adverse events. There were no dose-limiting toxicities found, and only one patient stopped treatment due to side effects. Of the side effects observed, the most common were asymptomatic lipase, visceral venous thrombosis and diverticulitis, all of which were minimal. The medication also appears to be well tolerated by patients with ET who could not take cytoreductive therapy.
Dr. Gerds is quick to point out that this is very preliminary study data that needs correlating with improvements in myelofibrosis-free survival, clot-free survival and overall survival. However, these early results are quite encouraging. “Given the favorable toxicity profile of INCA44989, the world is our oyster in terms of where we can take this therapy. We’re not limited by additive or combinatorial toxicities, so that broadens the possibilities for how this treatment can be developed,” Dr. Gerds says.
What’s next
This monoclonal antibody is just one example of how to treat somewhat rare myeloproliferative neoplasms like ET and MF. The field is rapidly evolving.
The myelofibrosis cohort study is still enrolling, with top-line results expected around the end of the year. A parallel study outside of Cleveland Clinic is also underway investigating INCA44989 in combination with ruxolitinib. “As we bring these findings together over the next year or so, that will help identify what direction this therapy will take next,” says Dr. Gerds.
“There is also ongoing research into bispecific antibodies as well as engineered cells like CAR T-cell therapy that may build on top of a monoclonal antibody. I expect there will be a huge wave of change in this area over the next five to ten years,” explains Dr. Gerds.
Why Kate Middleton is ‘modern day Princess Diana?’ Expert reveals
Kate Middleton is lauded for her grace and demeanor by a former Royal staff.
The Princess of Wales has been a ‘Queen in waiting’ ever since she met Prince William at a tender age of 22, says royal butler Grant Harold, who has seen the couple blossoming together
He tells The Mirror : “That girl was a Queen in waiting in every aspect. She is the perfect Queen material and you can so obviously see that. Everything about her – the way she carried herself, the way she spoke, the way she interacted with people, her kindness, her beauty – she was, if I can say, the modern day Princess Diana.”
He then compared Kate to Princess Diana, adding: “Diana used to do things at Sandringham to make the staff laugh by poking her head out the window and pulling faces, and Kate was doing the same kind of thing. She is everything you can imagine, she is a beautiful and intelligent woman.”
Key stat: Streaming accounts for almost half (45.3%) of total US time spent with ad-supported TV, according to a July report from Nielsen.
Beyond the chart:
YouTube dominates streaming, making up 13.4% of US time spent with streaming TV, according to July data from Nielsen. Netflix is the second-highest streamer, making up 8.8% of time spent.
A third of US adults spend one to two hours a day streaming TV, according to April data from Attest.
Use this chart: Marketers can use this chart as justification to prioritize CTV platforms in their media mix, especially for campaigns targeting younger, digital-first audiences. Media planners should reevaluate linear TV investments and shift toward platforms like YouTube, Hulu, and FAST services that dominate the streaming ad space.
WOMEN in Pakistan constitute 48.5 per cent of the population but face systemic disadvantages in education, healthcare and economic participation. To realise the country’s full potential, increasing women’s economic participation is critical.
Pakistan hit rock bottom in the World Economic Forum’s 2025 Global Gender Gap Index out of 148 countries, with 56.7pc gender parity; it has closed only 2.3pc of the gap since 2006. It ranks below Sudan, Chad, Iran, Guinea and Congo. In South Asia, Bangladesh holds the 24th position, demonstrating a far more favourable gender equality landscape. This is the second year in a row that Pakistan’s gender parity score has declined.
This alone is a damning indictment of the little progress made — despite millions being poured into gender equality initiatives by international development agencies. However, the deeper problem is not lack of funding, but the misuse of a noble narrative to justify wasteful development programming. It should lead to deep introspection about why gender equality efforts keep failing.
Take, for example, the Asian Development Bank’s (ADB) initiative with Pakistan’s National Transmission and Despatch Company to increase female participation in technical and leadership roles.
A $182,000 technical assistance grant — part of the broader Power Transmission Enhancement Investment Programme — was awarded to support ‘gender mainstreaming’ through drafting a workplace gender policy, training 20pc of female staff and auditing an internship programme. This reads more like an HR department’s annual plan than a serious development intervention. Any functional organisation with a competent HR team can perform such tasks.
So why is our ailing power sector the testing ground for gender experiments scripted in distant multilateral offices?
The broader problem is a development culture that rewards symbolism over substance.
This is not an isolated case. ADB partnered with the State Bank of Pakistan (SBP) to develop a Women Entrepreneurs Finance Code under a Women-Inclusive Financial Sector Development Programme funded through a $5.5m grant and $150m loan.
In June 2025, another $350m loan was approved to support women’s access to finance and provide credit to women-led micro SMEs. The code, launched with fanfare, is merely a declaration of intent to close financing gaps by designating a leader to monitor data and introduce targets.
While gender-responsive finance is a valid policy goal, was this multimillion-dollar donor intervention truly necessary when the SBP already has the legal mandate, institutional capacity and technical expertise to design such policies? Or is this just donor funding chasing headlines, not solutions?
Has the central bank run out of ideas to promote financial inclusion, which it championed until a decade ago when the Economist Intelligence Unit rated Pakistan’s microfinance regulatory framework the best in the world in 2010 and 2011, and the third best in 2013 and 2014? Either way, such supply-driven initiatives only weaken state institutions.
ADB has been involved in Pakistan’s financial sector since 2000, when it launched a $150m microfinance sector development programme to provide financial services to the poor, especially women. The World Bank is also actively involved in gender empowerment projects, focusing on education, economic participation and access to finance.
In March this year, the World Bank approved a $102m loan to enhance access to microcredit and support the resilience of the microfinance sector. ADB and World Bank have extended loans for the same purpose for over 25 years. Similarly, bilateral donors continue to fund gender empowerment initiatives. The UK’s FCDO-owned Karandaaz also invests in profitable banks and established corporates to increase access to SME finance, including for women entrepreneurs.
This unneeded donor exuberance in Pakistan’s most profitable financial sector underscores a lack of interest in addressing core development challenges. These initiatives mainly advance the careers and networks of donor staff, consultants and local counterparts. There is clearly a problem when aid becomes a lucrative industry. It absolves the government of its responsibility to work for the welfare of its citizens. This aid addiction — fostered by international donors — has contributed to institutional decay, economic stagnation and insurmountable debt.
In fact, the actual outcomes of donor programmes implemented over the past decades show deteriorating trends. Pakistan’s credit-to-GDP ratio fell from 27pc in 2008 to 9pc in 2024 — the lowest among emerging countries. Credit remains concentrated in large corporates, with nearly 70pc allocated to manufacturing.
This reflects banks’ disconnect from the broader economy as well as the ineffectiveness of SBP regulation and donor involvement in the financial sector. More troubling is the steady decline in SMEs’ access to finance; their share of total private sector credit dropped from 17pc in the mid-2000s to just 6pc in 2024. The number of SME borrowers also declined from 185,000 in 2007 to 172,000 in 2024. Most financing is directed towards medium enterprises.
The broader problem is a development culture that rewards symbolism over substance. Pakistan’s addiction to foreign aid has fostered a policy environment where any externally funded programme is welcomed without scrutiny. Frivolous projects are designed to please donors, not solve real problems, reflecting waste and abuse. Whether in foreign-funded tax reforms, energy sector financial sustainability projects, or gender mainstreaming campaigns, the pattern is consistent: poor design, poor results.
Tragically, these projects are celebrated with MoUs, photo-ops, and social media hype, while the women they claim to empower remain invisible. This isn’t just inefficient — it’s unethical. Tokenism empowers donor staff, consultants and policymakers, not women; it reduces gender equality to a funding checkbox. Worse, they hide behind bizarre buzzwords like ‘gender-responsive climate finance’ or ‘gender-transformative value chains’ — jargon-masking emptiness.
We must not confuse real gender empowerment with bureaucratic parody. Genuine change means women’s access to education and healthcare, legal rights (especially inheritance), protection from violence, and more women in the workforce — not elite seminars, lavish launches, or pricey consultants churning out reports that nobody reads. Pakistan needs genuine reforms, not donor-driven theatre. And it is time we start calling out the phoney feminism that masquerades as development.
The writer is the author of The Shady Economics of International Aid. He is a former senior adviser of the IMF and ex-chief economist of the SBP.
Is the beef between Gavin Adcock and Charley Crockett over?
It appears so. Adcock posted a video to Instagram on Thursday (Aug. 21), noting that Crockett is attempting to bury the hatchet. The video clip shows Adcock sitting in a backstage area and holding a large bouquet of roses and a copy of Crockett’s new album Dollar a Day. Adcock poked fun at Crockett while accepting flowers and vinyl.
“Apparently last night Charley Crockett was supposed to play the venue that we’re playing tonight, but he didn’t sell enough tickets, so he had to move to a smaller venue down the street — but before he left he sent me 60 roses and a $3 vinyl, so shout-out to Charley Crockett,” Adcock says with a smile. “I appreciate ya, buddy.”
Adcock’s tour schedule has him slated to perform at WAVE in Wichita, Kansas, on Thursday night, while Crockett performed at Wichita’s The Cotillion on Wednesday. Crockett had previously been scheduled to perform at WAVE back in May, but the show was postponed and moved to The Cotillion.
In June, Adcock had some thoughts to share about Beyoncé’s Grammy-winning Cowboy Carter album during one of his concerts. Adcock blasted Bey’s project, which was keeping his own album out of the top three on Apple Music’s country albums chart at the time.
Earlier this week, Crockett issued a lengthy Instagram post that seemingly called out Adcock and other country stars who have spoken out against Cowboy Carter, and also defended Beyoncé. Crockett didn’t mention Adcock by name, but in his message he wrote, “I don’t need to put down a Black woman to advance my music. That’s just embarrassing to the idea of America and I got no respect for it.”
Adcock quickly fired back at Crockett on social media. He also didn’t mention Crockett by name, but wrote, “Somebody needs to tell the ‘act’ that has let out (the cover) of James town ferry 6 times he should just work on letting out quality original music. I got more cowsh– under my pinky then you have seen your whole f—in’ life. Hank sr called and asked about the cosplay cowboy.”
“Jamestown Ferry,” which Tanya Tucker first recorded in 1972, was included on Crockett’s 2017 album Lil G.L.’s Honky Tonk Jubilee and then on 2023’s Live From The Ryman, as well as a remixed version of the song on 2025’s Lonesome Drifter.
A spokesperson for Crockett had not returned Billboard‘s request for comment by press time to confirm whether the flowers and album came from him.
The moon is almost completely dark tonight, thanks to where we are in the lunar cycle.
The lunar cycle is a series of eight unique phases of the moon’s visibility. The whole cycle takes about 29.5 days, according to NASA, and these different phases happen as the Sun lights up different parts of the moon whilst it orbits Earth.
So let’s see what’s happening with the moon tonight, Aug. 22.
What is today’s moon phase?
As of Friday, Aug. 22, the moon phase is Waning Crescent, and only 1% will be lit up to us on Earth, according to NASA’s Daily Moon Observation.
We’re on day 29 of the lunar cycle, and with so little of the moon lit up, we won’t be able to spot anything tonight.
When is the next full moon?
The next full moon will be on Sept. 7. The last full moon was on Aug. 9.
What are moon phases?
According to NASA, moon phases are caused by the 29.5-day cycle of the moon’s orbit, which changes the angles between the Sun, Moon, and Earth. Moon phases are how the moon looks from Earth as it goes around us. We always see the same side of the moon, but how much of it is lit up by the Sun changes depending on where it is in its orbit. This is how we get full moons, half moons, and moons that appear completely invisible. There are eight main moon phases, and they follow a repeating cycle:
Mashable Light Speed
New Moon – The moon is between Earth and the sun, so the side we see is dark (in other words, it’s invisible to the eye).
Waxing Crescent – A small sliver of light appears on the right side (Northern Hemisphere).
First Quarter – Half of the moon is lit on the right side. It looks like a half-moon.
Waxing Gibbous – More than half is lit up, but it’s not quite full yet.
Full Moon – The whole face of the moon is illuminated and fully visible.
Waning Gibbous – The moon starts losing light on the right side.
Last Quarter (or Third Quarter) – Another half-moon, but now the left side is lit.
Waning Crescent – A thin sliver of light remains on the left side before going dark again.
In 2025, a major breakthrough came from Leipzig University, where genetic epidemiologist Markus Scholz led a sweeping genome-wide association meta-analysis involving over 21,000 individuals of European descent. This is the largest-ever genetic study on human scent perception. Participants were tested using 12 everyday smells (like clove, orange, cinnamon, peppermint, coffee, and fish) via scent pens. The researchers mapped these responses against genetic data and discovered 10 distinct genetic regions tied to the ability to detect specific odours, seven of which were previously unknown.
Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.
We often think people dislike a smell just because it’s strong. But scientists have discovered that strength and likeability are genetically independent traits. This means someone might find a scent subtle, yet completely revolting or very intense but still enjoyable. In a landmark study published in Nature Neuroscience, researchers found that different variants of the olfactory receptor gene OR10G4 altered how people responded to guaiacol, a smoky, campfire-like compound. Some people described it as cozy, nostalgic, and woody, while others said it smelled like burnt rubber or plastic.
Investors are avoiding Japan’s super-long bonds with lower coupons in a bearish trend that risks spreading to other tenors before they close their books at the end of next month.
Government bonds issued years before the Bank of Japan began quantitative tightening in the summer of 2024 are underperforming as their sub 1% coupons lose out to newer debt with fixed payouts twice as high.
